AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15115949 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 25
Study 11128820 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief acupuncture
Number of subjects: 50
Study 11128820 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 50
Study 9106572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 20
Study 9106572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9106572 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 20
Study 1437435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (0.15 mg/kg per dose) and ipratropium bromide (250 micrograms per dose)
Number of subjects: 69
Study 1437435 — intervention group
Group type: COMPARATOR
Intervention: Nebulized albuterol and normal saline (placebo)
Number of subjects: 69
Study 3083920 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeries booked at 10 minute intervals
Number of subjects: 623
Study 3083920 — intervention group
Group type: COMPARATOR
Intervention: Surgeries booked at 7.5 minute intervals
Number of subjects: 623
Study 3083920 — intervention group
Group type: COMPARATOR
Intervention: Surgeries booked at 5 minute intervals
Number of subjects: 623
Study 29849557 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mechanical tactile stimulation (MS)
Number of subjects: 19
Study 29849557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral mechanical tactile stimulation (MS)
Number of subjects: 19
Study 29849557 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubbing mechanical tactile stimulation (MS)
Number of subjects: 19
Study 29849557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical mechanical tactile stimulation (MS)
Number of subjects: 19
Study 29849557 — intervention group
Group type: EXPERIMENTAL
Intervention: Random mechanical tactile stimulation (MS)
Number of subjects: 19
Study 26646751 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of hydrocortisone (0.4‐0.6 mg/kg body weight/day)
Number of subjects: 47
Study 24892882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based training program
Number of subjects: 91
Study 24892882 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 91
Study 22149763 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) hydrated in recombinant human platelet-derived growth factor (rhPDGF)
Number of subjects: 17
Study 22149763 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) hydrated in sterile saline (control)
Number of subjects: 17
Study 19650962 — intervention group
Group type: EXPERIMENTAL
Intervention: Free healthy school lunch served to pupils over 4 months (January to May 2007)
Number of subjects: 150
Study 19650962 — intervention group
Group type: EXPERIMENTAL
Intervention: Free healthy school lunch
Number of subjects: 150
Study 19650962 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no free lunch)
Number of subjects: 150
Study 18355797 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) using the Vacuum-Assisted Closure (V.A.C.) system
Number of subjects: 162
Study 18355797 — intervention group
Group type: COMPARATOR
Intervention: Standard moist wound therapy (MWT)
Number of subjects: 162
Study 18355797 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 162
Study 16043008 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 200
Study 16043008 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed group
Number of subjects: 200
Study 16043008 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed participants
Number of subjects: 200
Study 16043008 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants taking prescribed medications
Number of subjects: 200
Study 16043008 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care pain management strategies
Number of subjects: 200
Study 12390105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 9
Study 12390105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12390105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 10 mg
Number of subjects: 9
Study 10090549 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 236
Study 10090549 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 236
Study 10090549 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at entry < 3 years
Number of subjects: 236
Study 10090549 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at entry > 3 years
Number of subjects: 236
Study 7800005 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial treatment (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, each given orally four times a day for one week)
Number of subjects: 100
Study 7800005 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial treatment
Number of subjects: 100
Study 7800005 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg orally per day for four weeks)
Number of subjects: 100
Study 7800005 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 100
Study 2129915 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct placement composite resin (Ful‐fil)
Number of subjects: 36
Study 2129915 — intervention group
Group type: COMPARATOR
Intervention: Direct composite resin inlay (Brillant D.I.)
Number of subjects: 36
Study 2129915 — intervention group
Group type: COMPARATOR
Intervention: Direct composite resin inlay (Ful‐fil)
Number of subjects: 36
Study 119526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol trinitrate (PTN)
Number of subjects: 28
Study 119526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine (NG)
Number of subjects: 28
Study 30948276 — intervention group
Group type: EXPERIMENTAL
Intervention: RB-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone + Bortezomib 1.3 mg/m2 intravenously or 1.6 mg/m2 subcutaneously on days 1 and 8 for cycles two to six)
Number of subjects: 918
Study 30948276 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone)
Number of subjects: 918
Study 30948276 — intervention group
Group type: EXPERIMENTAL
Intervention: RB-CHOP
Number of subjects: 918
Study 30948276 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 918
Study 30374690 — intervention group
Group type: EXPERIMENTAL
Intervention: List of important questions provided to relatives immediately after randomization.
Number of subjects: 394
Study 30374690 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group) without the list of questions.
Number of subjects: 394
Study 30374690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (list of questions)
Number of subjects: 394
Study 30374690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no list of questions)
Number of subjects: 394
Study 26894333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SBRT and ICBT
Number of subjects: 40
Study 25127655 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose warfarin for 3-6 days aiming for INR < 1.7
Number of subjects: 171
Study 25127655 — intervention group
Group type: COMPARATOR
Intervention: Interrupted warfarin for 5 days with LMWH bridging for 2.5 days
Number of subjects: 171
Study 22622649 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 μg/kg/min for 24 hours)
Number of subjects: 40
Study 22622649 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (0.5 μg/kg/min for 24 hours)
Number of subjects: 40
Study 19922961 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG (rosiglitazone 8 mg/d)
Number of subjects: 100
Study 19922961 — intervention group
Group type: EXPERIMENTAL
Intervention: EX (exercise training)
Number of subjects: 100
Study 19922961 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG + EX (rosiglitazone 8 mg/d plus exercise training)
Number of subjects: 100
Study 19922961 — intervention group
Group type: COMPARATOR
Intervention: CO (maintenance of habitual activities)
Number of subjects: 100
Study 17672962 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (500 mg four times daily for 3 days before surgery)
Number of subjects: 203
Study 15615872 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (140 mg/day; n=26)
Number of subjects: 50
Study 15615872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose; n=24)
Number of subjects: 50
Study 14601481 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopenia (n = 27)
Number of subjects: 81
Study 14601481 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis (n = 25)
Number of subjects: 81
Study 14601481 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 29)
Number of subjects: 81
Study 14601481 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopenia and Osteoporosis (n = 52 combined)
Number of subjects: 81
Study 9698950 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric lidocaine 50 mg/ml diluted with CSF 1:1 (Group L)
Number of subjects: 90
Study 9698950 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric mepivacaine 40 mg/ml (Group M)
Number of subjects: 90
Study 9698950 — intervention group
Group type: COMPARATOR
Intervention: hyperbaric bupivacaine 5 mg/ml (Group B)
Number of subjects: 90
Study 8681269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy using a fluorescent light box (2500 lux for 2 hours per day)
Number of subjects: 0
Study 8681269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy using a fluorescent light box (10,000 lux for 30 minutes)
Number of subjects: 0
Study 8681269 — intervention group
Group type: EXPERIMENTAL
Intervention: Light visors and other head‐mounted devices
Number of subjects: 0
Study 8681269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 8681269 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐fenfluramine
Number of subjects: 0
Study 8681269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 8681269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dawn simulation
Number of subjects: 0
Study 2091459 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 82
Study 2091459 — intervention group
Group type: COMPARATOR
Intervention: Drop-in (DI) center
Number of subjects: 82
Study 158570 — intervention group
Group type: EXPERIMENTAL
Intervention: tretinoin lotion 0.05% applied in the morning and benzoyl peroxide 5% and 10% applied at night
Number of subjects: 250
Study 31833175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 60
Study 31833175 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 60
Study 31833175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Clopidogrel
Number of subjects: 60
Study 31127955 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Shape system followed by MM1500
Number of subjects: 40
Study 31127955 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc system followed by MM1500
Number of subjects: 40
Study 31127955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic activation with MM1500 in the first group
Number of subjects: 40
Study 31127955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic activation with Eddy in the second group
Number of subjects: 40
Study 31127955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic activation with MM1500 in the third group
Number of subjects: 40
Study 31127955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic activation with Eddy in the fourth group
Number of subjects: 40
Study 31127955 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 40
Study 28463827 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine lock solution
Number of subjects: 163
Study 28463827 — intervention group
Group type: COMPARATOR
Intervention: Standard saline solution (Control)
Number of subjects: 163
Study 26110667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography and MR imaging
Number of subjects: 36185
Study 26110667 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 36185
Study 23894905 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for parents (3 educational sessions)
Number of subjects: 0
Study 23894905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study 22779096 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% lotion
Number of subjects: 144
Study 22779096 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% cream
Number of subjects: 144
Study 19958063 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits for reducing selected antibiotics (14 practices)
Number of subjects: 28
Study 19958063 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits for improving antidepressant prescribing (14 practices)
Number of subjects: 28
Study 19958063 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 practices not receiving educational outreach)
Number of subjects: 28
Study 17944686 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/saquinavir/ritonavir (LPV/SQV/r; 400/1000/100 mg bid)
Number of subjects: 64
Study 17944686 — intervention group
Group type: COMPARATOR
Intervention: indinavir/ritonavir (IDV/r; 800/100 mg bid) plus two NRTIs
Number of subjects: 64
Study 17944686 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/saquinavir/ritonavir (LPV/SQV/r)
Number of subjects: 64
Study 17944686 — intervention group
Group type: COMPARATOR
Intervention: indinavir/ritonavir (IDV/r) plus two NRTIs
Number of subjects: 64
Study 15356029 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d) for 6 months in prepubertal girls
Number of subjects: 57
Study 15356029 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/d) for 12 months in postpubertal girls
Number of subjects: 57
Study 15356029 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated) in prepubertal girls
Number of subjects: 57
Study 15356029 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated) in postpubertal girls
Number of subjects: 57
Study 11308399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 75
Study 11308399 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (RT)
Number of subjects: 75
Study 11308399 — intervention group
Group type: COMPARATOR
Intervention: Placebo Treatment
Number of subjects: 75
Study 9401591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone-10 (Q10) supplementation
Number of subjects: 18
Study 9401591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8323306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroactive dressing
Number of subjects: 50
Study 8323306 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (bacitracin plus Band‐Aid)
Number of subjects: 50
Study 3479490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed composite restoration placed over carious lesion
Number of subjects: 0
Study 3479490 — intervention group
Group type: COMPARATOR
Intervention: Traditional outline-form (unsealed) amalgam restoration
Number of subjects: 0
Study 3479490 — intervention group
Group type: COMPARATOR
Intervention: Ultraconservative sealed amalgam restoration
Number of subjects: 0
Study 31176727 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-encoding stress (cold pressor for 3 min)
Number of subjects: 80
Study 31176727 — intervention group
Group type: COMPARATOR
Intervention: Control task (warm water for 3 min)
Number of subjects: 80
Study 28700805 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (50 or 70 mg)
Number of subjects: 418
Study 28700805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 28700805 — intervention group
Group type: COMPARATOR
Intervention: Lisdexamfetamine vs Placebo
Number of subjects: 418
Study 26525419 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated COPD disease management programme (RECODE)
Number of subjects: 1086
Study 26525419 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1086
Study 24136905 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie labeling policy in Philadelphia
Number of subjects: 0
Study 21455808 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxophone-shaped backstrap electrode for vagal stimulation (16 NaR)
Number of subjects: 24
Study 21455808 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical and rigid electrode (14 NaR)
Number of subjects: 24
Study 21455808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both electrodes
Number of subjects: 24
Study 17851460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus fermented milk
Number of subjects: 29
Study 17851460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificially acidified milk)
Number of subjects: 29
Study 16473558 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release divalproex sodium (divalproex-ER) every 12 hours (q12h)
Number of subjects: 24
Study 16473558 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily divalproex-ER
Number of subjects: 24
Study 15246129 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group sessions
Number of subjects: 0
Study 15246129 — intervention group
Group type: COMPARATOR
Intervention: Program mainly by mail
Number of subjects: 0
Study 10885442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum oil (hypericin 110 microg/mL)
Number of subjects: 16
Study 10885442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum ointment (hypericin 30 microg/mL)
Number of subjects: 16
Study 8866087 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the nasogastric tube upon tracheal extubation
Number of subjects: 80
Study 8866087 — intervention group
Group type: COMPARATOR
Intervention: Retention of the nasogastric tube until the passage of flatus
Number of subjects: 80
Study 1468386 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (group M) - 50 micrograms/kg per h, increased to 100 micrograms/kg per h if needed
Number of subjects: 95
Study 1468386 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (group P) - 100 micrograms/kg as required
Number of subjects: 95
Study 1468386 — intervention group
Group type: COMPARATOR
Intervention: Morphine with Pancuronium (group M+P)
Number of subjects: 95
Study 6331136 — intervention group
Group type: COMPARATOR
Intervention: 40 mg purified brain gangliosides for six months
Number of subjects: 40
Study 30976851 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day, n=12, MET group)
Number of subjects: 24
Study 30976851 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day, n=12, CONT group)
Number of subjects: 24
Study 30976851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12, PLA group)
Number of subjects: 24
Study 29991403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with kanamycin (KM)
Number of subjects: 20
Study 29991403 — intervention group
Group type: COMPARATOR
Intervention: Kanamycin (KM) without lidocaine
Number of subjects: 20
Study 27812621 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rotation
Number of subjects: 56
Study 27812621 — intervention group
Group type: COMPARATOR
Intervention: 360° CCW ‐ 30° CW
Number of subjects: 56
Study 27812621 — intervention group
Group type: COMPARATOR
Intervention: 270° CCW ‐ 30° CW
Number of subjects: 56
Study 27812621 — intervention group
Group type: COMPARATOR
Intervention: 150° CCW ‐ 30° CW
Number of subjects: 56
Study 25033565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (administered for three days)
Number of subjects: 2
Study 25033565 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (administered for three days)
Number of subjects: 2
Study 25033565 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (sub-chronic administration for 6 days)
Number of subjects: 2
Study 22423611 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi-SP (sulphadoxine-pyrimethamine)
Number of subjects: 5882
Study 20417447 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20mg
Number of subjects: 753
Study 20417447 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 80mg
Number of subjects: 753
Study 17021587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous peripheral nerve stimulation (HF-TPNS) for 10 minutes
Number of subjects: 18
Study 17021587 — intervention group
Group type: COMPARATOR
Intervention: Control session (no stimulation)
Number of subjects: 18
Study 16152757 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 3 MIU subcutaneously three times a week plus 100 mg MMPD (every 8 h) for 4 weeks
Number of subjects: 54
Study 16152757 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 3 MIU subcutaneously three times a week plus 300 mg MMPD (every 8 h) for 4 weeks
Number of subjects: 54
Study 16152757 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha 3 MIU subcutaneously three times a week alone
Number of subjects: 54
Study 11966932 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (250 mg) and Metronidazole (200 mg) (AM)
Number of subjects: 66
Study 11966932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate capsules and Metronidazole (PM)
Number of subjects: 66
Study 11966932 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin and Calcium Lactate tablets (AP)
Number of subjects: 66
Study 11966932 — intervention group
Group type: COMPARATOR
Intervention: Lactate and Calcium Lactate (PP)
Number of subjects: 66
Study 11966932 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (AM)
Number of subjects: 66
Study 11966932 — intervention group
Group type: EXPERIMENTAL
Intervention: PM
Number of subjects: 66
Study 11966932 — intervention group
Group type: EXPERIMENTAL
Intervention: AP
Number of subjects: 66
Study 11966932 — intervention group
Group type: COMPARATOR
Intervention: PP
Number of subjects: 66
Study 11966932 — intervention group
Group type: EXPERIMENTAL
Intervention: AM
Number of subjects: 66